Who are Protalix BioTherapeutics, Inc.'s main suppliers?

Protalix BioTherapeutics, Inc. (PLX) key suppliers include: CHIESI. View the full supplier network at chainsifter.com/chain/PLX.

Who are Protalix BioTherapeutics, Inc.'s major customers?

Protalix BioTherapeutics, Inc. (PLX) key customers include: CHIESI, CHIESI-GLOBAL-RARE-DISEASES, FIOCRUZ, Pfizer Inc., Pfizer Inc.. View the full customer network at chainsifter.com/chain/PLX.

What sector is Protalix BioTherapeutics, Inc. in?

Protalix BioTherapeutics, Inc. (PLX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

PLX Supply Chain: Protalix BioTherapeutics, Inc. Suppliers & Customers

1Suppliers

5Customers

3Debt Items

20Related Chains

Protalix BioTherapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CHIESI	CHIESI	92%	Revenues from license and R&D services were as follows... The increase in revenues from license and R&D services for the three months ended March 31, 2026 compared to license and R&D services for the…

Protalix BioTherapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
CHIESI	CHIESI	92%	Revenues from customers include $3,513 thousand from Chiesi (Italy) for Fabry disease in 2026 and $0 thousand in 2025.
CHIESI-GLOBAL-RARE-DISEASES	CHIESI-GLOBAL-RARE-DISEASES	92%	the Company, issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A.
FIOCRUZ	FIOCRUZ	92%	Revenues from customers include $2,454 thousand from Fiocruz (Brazil) for Gaucher disease in 2026 and $3,016 thousand in 2025.
PFE	Pfizer Inc.	92%	Revenues from customers include $1,452 thousand from Pfizer (Ireland) for Gaucher disease in 2026 and $6,979 thousand in 2025.
PFE	Pfizer Inc.	92%	Reciprocal relationship from PFE graph: Reciprocal relationship from PLX graph: Reciprocal relationship from PFE graph: Reciprocal relationship from PLX graph: Reciprocal relationship from PFE graph:…

Protalix BioTherapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
PLX-DEBT	Debt stack $8.5M	90%	Market cache reports total debt of $8.5M.
PLX-DEBT-11818	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
PLX-DEBT-11817	Warrants outstanding: 845000	90%	xbrl warrant detail from xbrl 2024-12-31.

Protalix BioTherapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Protalix BioTherapeutics, Inc..

Protalix BioTherapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
PLX-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 100 tracked holders.

Protalix BioTherapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
CSTE	Caesarstone Ltd.	100.00	2

Protalix BioTherapeutics, Inc. Supply Chain